Predict your next investment

Corporation
HEALTHCARE | Biotechnology
updatepharma.com

See what CB Insights has to offer

Stage

Unattributed | Alive

Total Raised

$40K

Last Raised

$40K | 6 yrs ago

About Update Pharma

Update Pharma is a clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs. The company's lead compound, UPI-928 is a compound originally developed more than 20 years ago. It has demonstrated clinical efficacy and acceptable tolerability in Acute Myeloid Leukemia (AML) and other oncology indications including refractory breast cancer, myeloma, and ovarian cancer.

Update Pharma Headquarter Location

77 Bissell Road

Lebanon, New Jersey, 08833,

United States

917-653-0470

Latest Update Pharma News

Update Pharma and Resolute Oncology Sign Binding Term Sheet to Merge

Feb 21, 2019

Details to Be Presented at Rodman and Renshaw Conference Rodman & Renshaw Global Investment Conference 2013 September 09, 2013 08:30 AM Eastern Daylight Time RENO, Nev.--( BUSINESS WIRE )--Update Pharma Inc. has announced today it has entered into a binding term sheet for a merger with Resolute Oncology, Inc. (REON). Under the agreed upon terms, Update will merge with REON and will own 70% of the surviving entity. Update will appoint 3 board members and REON will appoint two. Following the completion of diligence, and the resolution of certain conditions specified as terms, a definitive agreement between the parties will consummate the merger. The combined entity, doing business under the name of Resolute Oncology Inc., will be comprised of a proprietary drug development capability initially dedicated to the development of its lead compound UPI-928 for the treatment of acute myeloid leukemia, recurrent breast cancer, and other indications as in addition to a specialty oncology pharma company that is currently selling products in the private oncology market in Europe. REON brings experience in the execution of a named patient program, and the combined entity will initiate a named patient program for UPI-928. “Update and Resolute are a natural fit for each other,” said Dr. John Rothman, CEO of Update Pharma. “Resolute provides revenues, access to the European oncology community, the ability to execute a named patient program, and other attributes that are useful to Update, and Update provides Resolute with a drug development capability that includes a proprietary agent in development that has demonstrated good tolerability and clinical activity in an extensive body of literature, and the ability for its clients to participate in the drug development process.” Additional details will be discussed at the Rodman and Renshaw Investor Conference at the Millennium Hotel in New York City on Tuesday, September 10th at 3:15 PM in room 7-03. About Update Pharma Inc.: Update Pharma Inc. is developing UPI-928, an agent developed in the 1980’s by Lederle Laboratories in 44 phase 1, 2 and 3 clinical trials, including 33 clinical trials at the National Cancer Institute. Despite an acceptable safety database of over 2,000 treated patients, over 70 peer reviewed clinical publications that demonstrated efficacy in leukemia, lymphoma breast and ovarian cancers and a marketing approval in France for the treatment of acute myeloid leukemia (AML), UPI-928 was never marketed. Update has filed new intellectual property on UPI-928 and intends to use existing regulatory mechanisms to accelerate the development process based upon the extensive body of historical data. Resolute Oncology Inc. (REON) Resolute Oncology is a specialty pharmaceutical company that has been recently formed to sell oncology drugs to the private market in Europe. Currently REON has introduced two agents in Germany that generate revenue, with two additional agents to be launched in 2013 and a fifth agent to be launched in 2014. Additionally, REON intends to bid on public tenders in the UK, France and Germany in 2014. Forward-Looking Statements Certain statements in this Press Release are "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include the risk for the Company to complete its development work, as well as the risks inherent in commercializing a new product (including technology risks, market risks, financial risks and implementation risks, and other risks and uncertainties affecting the Company), as well as other risks that have been disclosed by us and are customarily disclosed in SEC filings of publicly traded pharmaceutical companies. We disclaim any intention or obligation to revise any forward-looking statements, including, without limitation, financial estimates, whether as a result of new information, future events, or otherwise.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Update Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Update Pharma is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Update Pharma Patents

Update Pharma has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/25/2014

6/12/2018

Prodrugs, Experimental cancer drugs, Oncology, Amines, Cancer treatments

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/25/2014

00/00/0000

Grant Date

6/12/2018

00/00/0000

Title

Subscribe to see more

Related Topics

Prodrugs, Experimental cancer drugs, Oncology, Amines, Cancer treatments

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.